| Literature DB >> 35862693 |
Yingshan Chen1,2, Yongxuan Yao1,3, Kaitao Zhao4, Canyu Liu1,2, Yifei Yuan1,2, Hao Sun1,2, Dan Huang1,2, Yi Zheng5, Yuan Zhou1, Jizheng Chen1, Yun Wang1, Chunchen Wu6, Bixiang Zhang7, Yujuan Guan8, Feng Li8, Rongjuan Pei1, Xinwen Chen1,2,9.
Abstract
The biogenesis of covalently closed circular DNA (cccDNA) from relaxed circular DNA (rcDNA) is essential for chronic hepatitis B virus (HBV) infection. Different host DNA repair proteins are involved in the conversion of rcDNA to cccDNA. Here, we reported that the DNA repair factor poly(ADP-ribose) polymerase 1 (PARP1) is engaged in HBV cccDNA formation. PARP1 depletion remarkably impaired HBV replication and cccDNA synthesis. Inhibition of PARP1 poly (ADP-ribosylation) activity by olaparib suppressed cccDNA synthesis both in vitro and in vivo. Specifically, the early stage of cccDNA reservoir establishment was more sensitive to olaparib, suggesting that PARP1 participated in de novo cccDNA formation. Furthermore, PARP1 was activated by recognizing the rcDNA-like lesions directly and combined with other DNA repair proteins. The results presented proposed that the DNA damage-sensing protein PARP1 and poly(ADP-ribosylation) modification play a key role in cccDNA formation, which might be the target for developing the anti-HBV drug. IMPORTANCE The biogenesis and eradication of HBV cccDNA have been a research priority in recent years. In this study, we identified the DNA repair factor PARP1 as a host factor required for the HBV de novo cccDNA formation. HBV infection caused PARylation through PARP1 in Huh7-NTCP cells, primary human hepatocytes, and human-liver chimeric mice. We found that PARP1 could directly bind to the rcDNA lesions and was activated, PARylating other DNA repair proteins. We address the importance of PARP1-mediated PARylation in HBV cccDNA formation, which is a potential therapeutic target for chronic hepatitis B.Entities:
Keywords: DNA repair system; HBV; PARP1; PARylation; cccDNA
Mesh:
Substances:
Year: 2022 PMID: 35862693 PMCID: PMC9278152 DOI: 10.1128/jvi.00585-22
Source DB: PubMed Journal: J Virol ISSN: 0022-538X Impact factor: 6.549